Twenty three speakers from 10 countries share the latest insights and treatment strategies for neurodegenerative brain diseases

Held over two days starting June 5 in collaboration with GEoPD, an international consortium leading Parkinson’s disease genetics research

▲ Asan Medical Center will host the Parkinson and Alzheimer Center Symposium over two days beginning June 5, bringing together global experts to discuss the latest advances and future treatment strategies for neurodegenerative diseases.

As populations age, the number of patients living with neurodegenerative brain disorders such as Parkinson’s disease and Alzheimer’s disease continues to rise. The growing overlap of symptoms, including cognitive impairment, sleep disturbances, and delusions, has underscored the need for more accurate diagnosis and integrated treatment approaches. Against this backdrop, a scientific symposium will bring together experts to discuss the latest advances and future therapeutic strategies for both diseases.

Asan Medical Center will host the 2026 Annual Symposium of the AMC Parkinson and Alzheimer Center from June 5 to 6 at the Grand Auditorium of the East Building. The two day event will provide a platform for sharing the latest research findings and clinical perspectives on Parkinson’s disease and Alzheimer’s disease.

This year’s symposium will be held in collaboration with the Genetic Epidemiology of Parkinson’s Disease (GEoPD), a global research consortium comprising more than 60 institutions across six continents, adding further academic depth and international significance to the event.

A distinguished lineup of 23 leading experts in neurology from 10 countries will participate as speakers, including Pamela McLean of the Mayo Clinic, Christine Klein of the University of Lübeck, Rejko Krüger of the University of Luxembourg, and Suzanne Lesage of the Sorbonne University. They will be joined by other internationally renowned researchers and clinicians to share the latest developments in neurodegenerative disease research and treatment.

On the first day, the symposium will feature four sessions covering the identification of novel Parkinson’s disease genes, the therapeutic application of alpha synuclein in Parkinson’s disease, molecular insights into Parkinson’s disease and emerging treatment approaches, and the decoding of omics data with AI driven data integration in Parkinson’s disease research.

The second day will focus on the latest trends and future directions in Parkinson’s disease genetics, with sessions exploring the evolving landscape of GEoPD and Parkinson’s disease genetics research, opportunities for expanding genetic studies in Parkinson’s disease, and genetic mechanisms of the disease revealed through family based research and artificial intelligence.

Director Sun Ju Chung of the AMC Parkinson and Alzheimer Center and Professor of the Department of Neurology at Asan Medical Center said, “We hope this symposium will further promote academic exchange among researchers studying Parkinson’s disease and Alzheimer’s disease, while serving as an important catalyst for future therapeutic development and research collaboration.”

The AMC Parkinson and Alzheimer Center provides integrated care for patients with Parkinson’s disease and Alzheimer’s disease through a multidisciplinary team of specialists from 11 departments, including Neurology, Neurosurgery, and Rehabilitation Medicine. By bringing together expertise across disciplines, the center delivers comprehensive diagnosis, treatment, and long term disease management.